Volume 29, Number 2—February 2023
Dispatch
Longitudinal Analysis of Electronic Health Information to Identify Possible COVID-19 Sequelae
Table
Diseases and codes | Rate increase relative to pre–COVID-19 rate (SE)† |
Post–COVID-19 rate, encounters/1,000 person-months |
|||||
---|---|---|---|---|---|---|---|
60–89 d | 90–119 d | 120–149 d | 60–89 d | 90–119 d | 120–149 d | ||
Certain infectious and parasitic diseases | |||||||
B97.21: SARS-associated coronavirus as the cause of diseases classified elsewhere | 28.7 (12.8) | 31.9 (15.6) | 82.2 (39.5) | 0.22 | 0.24 | 0.63 | |
B94.8: Sequelae of other specified infectious and parasitic diseases | 15.4 (4.5) | 17 (5.1) | 11.6 (4.2) | 0.26 | 0.29 | 0.20 | |
A41.53: Sepsis due to Serratia | 6 (3.9) | NS | NS | 0.60 | NS | NS | |
A41.89: Other specified sepsis | 2.8 (0.5) | NS | NS | 0.69 | NS | NS | |
B34.2: Coronavirus infection, unspecified | 2 (0.6) | 2.4 (0.7) | NS | 0.24 | 0.29 | NS | |
R65.21: Severe sepsis with septic shock |
1.5 (0.2) |
NS |
NS |
1.29 |
NS |
NS |
|
Diseases of blood and blood-forming organs and certain disorders involving the immune mechanism | |||||||
D84.821: Immunodeficiency due to drugs |
7.9 (6.0) |
NS |
NS |
0.30 |
NS |
NS |
|
Diseases of the circulatory system | |||||||
B33.24: Viral cardiomyopathy | 9.8 (8.8) | NS | NS | 0.30 | NS | NS | |
I46.8: Cardiac arrest due to other underlying condition | 4.8 (2.3) | 3.5 (1.9) | NS | 0.70 | 0.50 | NS | |
I46.9: Cardiac arrest, cause unspecified | 4.6 (0.9) | 3.7 (0.9) | 4.5 (1.1) | 0.40 | 0.32 | 0.38 | |
I40.0: Infective myocarditis |
NS |
12.6 (10.6) |
NS |
NS |
0.40 |
NS |
|
Diseases of the digestive system | |||||||
K20.91: Esophagitis, unspecified with bleeding | 19.8 (18.4) | NS | NS | 0.30 | NS | NS | |
K21.00: Gastro-esophageal reflux disease with esophagitis, without bleeding | 5.7 (1.3) | 6.1 (1.5) | 5.7 (1.7) | 0.29 | 0.31 | 0.29 | |
K20.90: Esophagitis, unspecified without bleeding | 3.1 (1.4) | 5.8 (2.3) | NS | 0.70 | 0.13 | NS | |
K00.7: Teething syndrome |
NS |
4 (2.3) |
NS |
NS |
0.50 |
NS |
|
Diseases of the genitourinary system | |||||||
N18.31: Chronic kidney disease, stage 3a | 4 (1.4) | 5.1 (1.9) | 6.4 (2.2) | 0.14 | 0.18 | 0.22 | |
N18.30: Chronic kidney disease, stage 3 unspecified | 3.6 (0.3) | 3.8 (0.4) | 4.2 (0.5) | 1.83 | 1.91 | 2.13 | |
N18.32: Chronic kidney disease, stage 3b | 2.5 (1.0) | 3.2 (1.2) | 5.1 (1.9) | 0.90 | 0.12 | 0.19 | |
Diseases of the musculoskeletal system and connective tissue | |||||||
M62.59: Muscle wasting and atrophy, not elsewhere classified, multiple sites | NS | 4.1 (2.1) | NS | NS | 0.10 | NS | |
M65.071: Abscess of tendon sheath, right ankle and
foot |
NS |
NS |
280.3 (550.3) |
NS |
NS |
0.10 |
|
Diseases of the nervous system | |||||||
G62.81: Critical illness polyneuropathy | 11.8 (6.8) | 9.1 (6.8) | NS | 0.70 | 0.50 | NS | |
G93.3: Postviral fatigue syndrome | 6.8 (2.5) | 4.2 (2.1) | NS | 0.12 | 0.70 | NS | |
G72.81: Critical illness myopathy | 5 (1.5) | NS | NS | 0.30 | NS | NS | |
R51.9: Headache, unspecified |
2.6 (0.3) |
3.9 (0.3) |
3.9 (0.4) |
1.47 |
2.23 |
2.23 |
|
Diseases of the respiratory system | |||||||
J12.81: Pneumonia due to SARS-associated coronavirus | 8.5 (3.6) | NS | NS | 0.90 | NS | NS | |
J80: Acute respiratory distress syndrome | 7.4 (2.9) | 3.9 (1.7) | NS | 0.32 | 0.17 | NS | |
J95.851: Ventilator associated pneumonia | 5.2 (2.4) | 4 (2.1) | NS | 0.90 | 0.70 | NS | |
J12.89: Other viral pneumonia |
NS |
16.1 (2.6) |
11 (2.0) |
NS |
1.33 |
0.91 |
|
Diseases of skin and subcutaneous tissue | |||||||
L65.9: Nonscarring hair loss, unspecified | 2.4 (0.5) | 3.5 (0.7) | 2.3 (0.6) | 0.36 | 0.54 | 0.35 | |
L89.153: Pressure ulcer of sacral region, stage 3 | 1.7 (0.4) | NS | NS | 0.42 | NS | NS | |
L89.154: Pressure ulcer of sacral region, stage 4 |
1.6 (0.3) |
NS |
NS |
0.68 |
NS |
NS |
|
Endocrine, nutritional, and metabolic diseases | |||||||
E87.71: Transfusion associated circulatory overload |
4.9 (3.0) |
NS |
NS |
0.40 |
NS |
NS |
|
Mental, behavioral, and neurodevelopmental disorders | |||||||
F10.139: Alcohol abuse with withdrawal, unspecified |
8.8 (7.6) |
NS |
NS |
0.30 |
NS |
NS |
|
Neoplasms | |||||||
C83.90: Non-follicular (diffuse) lymphoma, unspecified,
unspecified site |
411 (807) |
272.6 (535.2) |
NS |
0.14 |
0.90 |
NS |
|
Symptoms, signs, and abnormal clinical and laboratory findings, not elsewhere classified | |||||||
R74.01: Elevation of liver transaminase levels | 4.8 (1.2) | 5 (1.4) | 6.5 (1.9) | 0.21 | 0.21 | 0.28 |
*Results are significant at p<0.05. Diagnoses are limited to those with RRs significantly increased at >60 d. Clinical Classification Software Refined categories were taken from Agency for Healthcare Research and Quality Clinical Classifications Software Refined (https://www.hcup-us.ahrq.gov/toolssoftware/ccsr/ccs_refined.jsp). NS, not significant; RR, relative rate. †A specific diagnosis is counted for each patient encounter so that 1 patient might contribute >1 diagnosis if they were admitted for that diagnosis more than once during time period of interest.
1These authors contributed equally to this article.
Page created: November 18, 2022
Page updated: January 23, 2023
Page reviewed: January 23, 2023
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.